Recombinant Interleukin-12
Pancreatic Polypeptide Tumor
National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Pancreatic Polypeptide Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus University of Southern California | Phase 2 | B |
Everolimus Emory University | Phase 2 | B |
Regorafenib University of Southern California | Phase 2 | B |
Capecitabine ECOG-ACRIN Cancer Research Group | Phase 2 | B |
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
View all 15 →
Same molecule, other indications
Recombinant Interleukin-12 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →